Literature DB >> 10465666

Glycoaminoglycan (GAG) deficiency in protective barrier as an underlying, primary cause of ulcerative colitis, Crohn's disease interstitial cystitis and possibly Reiter's syndrome.

A L Russell.   

Abstract

Ulcerative colitis, Crohn's disease and interstitial cystitis share many common features, the most important of which is a defect in the glycoaminoglycan (GAG) defensive barrier. This defect allows penetration of toxins causing localized inflammatory response, followed by fibrosis and distant pathological changes, together with a myriad of biochemical and immunological changes. The latter has caused confusion as to etiology of the aforementioned disorders. This hypothesis is somewhat supported by the fact that agents such as glucosamine and pentosan polysulphate (Elmiron) that replace the GAG layer, improve the conditions. The potential for extrapolation of this hypothesis to atherosclerosis and arthropathies exists. There is a great danger in modern medical research that if one misses the wood for the trees, one becomes hopelessly lost in the minutiae of research. At present, it is embarrassing that ulcerative colitis (UC), Crohn's (CR) and interstitial cystitis (IC) are the cause of a great deal of morbidity and occasionally mortality, yet after intensive research, the etiology and effective treatment eludes us. The research in the past has focused extensively on inflammatory response in the mucosal lining, and biochemical, infective and immunological changes in the serum. This has led to a vast array of research pathways that seem at the present time to be totally lost and, might I say, aimless in direction, as a cause for these conditions, that remain amongst the most imperically treated in modern medicine. Another possible syndrome in this class would be Reiter's, which has many features in common with the above. The basic tenet of a GAG deficiency hypothesis is that, as shown in Figure 1A, an intact GAG layer provides, firstly, a mechanical and electrostatic defence against penetration of infective agents, toxins, antigenic protein moieties, etc. and, secondly, the prevention of extravasation of body fluid components. A degraded GAG layer is the start of the disease cascade of the above group of illnesses.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10465666     DOI: 10.1054/mehy.1997.0652

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  8 in total

1.  Treatment of ovalbumin-induced experimental allergic bronchitis in rats by inhaled inhibitor of secretory phospholipase A(2).

Authors:  D Shoseyov; H Bibi; S Offer; O Schwob; M Krimsky; M Kleiman; S Yedgar
Journal:  Thorax       Date:  2005-06-30       Impact factor: 9.139

2.  Fine structural characterization of chondroitin sulfate in urine of bladder pain syndrome subjects.

Authors:  Francesca Maccari; Dania Buzzega; Fabio Galeotti; Nicola Volpi
Journal:  Int Urogynecol J       Date:  2011-08-02       Impact factor: 2.894

Review 3.  Pentosan polysulfate: a review of its use in the relief of bladder pain or discomfort in interstitial cystitis.

Authors:  Vanessa R Anderson; Caroline M Perry
Journal:  Drugs       Date:  2006       Impact factor: 9.546

4.  Determination of urinary hexosamines for diagnosis of bladder pain syndrome.

Authors:  Dania Buzzega; Francesca Maccari; Fabio Galeotti; Nicola Volpi
Journal:  Int Urogynecol J       Date:  2012-04-21       Impact factor: 2.894

5.  Sulfated glycosaminoglycans of the vagina and perineal skin in pre- and postmenopausal women, according to genital prolapse stage.

Authors:  Leonardo R P S Bezerra; Paulo C Feldner; Lea M Kati; Manoel J B C Girão; Marair G Sartori; Edmund C Baracat; Geraldo Rodrigues de Lima; Helena B Nader; Carl P Dietrich
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2004 Jul-Aug

6.  Hyaluronan treatment of interstitial cystitis/painful bladder syndrome.

Authors:  Claus R Riedl; Paul F Engelhardt; Kurosch L Daha; Nike Morakis; Heinz Pflüger
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2007-12-21

7.  Prevention of sinonasal inflammation by a synthetic glycosaminoglycan.

Authors:  Abigail Pulsipher; Xuan Qin; Andrew J Thomas; Glenn D Prestwich; Siam Oottamasathien; Jeremiah A Alt
Journal:  Int Forum Allergy Rhinol       Date:  2016-11-11       Impact factor: 3.858

8.  Prevention of anti-microbial peptide LL-37-induced apoptosis and ATP release in the urinary bladder by a modified glycosaminoglycan.

Authors:  Won Yong Lee; Justin R Savage; Jianxing Zhang; Wanjian Jia; Siam Oottamasathien; Glenn D Prestwich
Journal:  PLoS One       Date:  2013-10-30       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.